Horizon Discovery

The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.

In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.

The company said its product revenues for the year rose 101 percent while its services revenues rose 7 percent.

The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.

Horizon will develop NTRK fusion immunohistochemistry reference standards to be used in oncology assays.

Expanding the companies' pre-existing agreement will allow Horizon to use CRISPR in new products and services.

The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.

Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.

The technology is based on helitrons, a type of eukaryotic transposon that can incorporate multiple copies of a DNA sequence into a genome.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.